Glenmark
A new way for a new world

URGENT: DRUG RECALL

MUPIROCIN OINTMENT USP, 2%, 22 g Tube pack (OINTMENT) (NDC 68462-180-22)

August 30, 2024

Dear Customer,

This is to inform you of a voluntary recall to Wholesale level involving the following drug product:

Mupirocin Ointment USP, 2%

Sr. No.	NDC	Batch Number	Expiry Date
1	68462-180-22	19223615	Aug-2024
2	68462-180-22	19223537	Aug-2024
3	68462-180-22	19223544	Aug-2024
4	68462-180-22	19223568	Aug-2024
5	68462-180-22	19223593	Aug-2024
6	68462-180-22	19223641	Aug-2024
7	68462-180-22	19224055	Sep-2024
8	68462-180-22	19224281	Sep-2024
9	68462-180-22	19224307	Sep-2024
10	68462-180-22	19224321	Sep-2024
11	68462-180-22	19224341	Sep-2024
12	68462-180-22	19224467	Sep-2024
13	68462-180-22	19224525	Oct-2024
14	68462-180-22	19224542	Oct-2024
15	68462-180-22	19224560	Oct-2024
16	68462-180-22	19224580	Oct-2024
17	68462-180-22	19224990	Nov-2024
18	68462-180-22	19224998	Nov-2024
19	68462-180-22	19225014	Nov-2024
20	68462-180-22	19225033	Nov-2024
21	68462-180-22	19225293	Nov-2024

Glenmark Pharmaceuticals Inc. USA 750 Corporate Drive, Mahwah, NJ 07430
T: 1 201 684 8000 F: 1 201 831 0080 www.glenmarkpharma.com/usa

Sr. No.	NDC	Batch Number	Expiry Date
22	68462-180-22	19225304	Nov-2024
23	68462-180-22	19225320	Nov-2024
24	68462-180-22	19225349	Nov-2024
25	68462-180-22	19225367	Nov-2024
26	68462-180-22	19225379	Nov-2024
27	68462-180-22	19225401	Nov-2024
28	68462-180-22	19230115	Dec-2024
29	68462-180-22	19230123	Dec-2024
30	68462-180-22	19230132	Dec-2024
31	68462-180-22	19230137	Dec-2024
32	68462-180-22	19230167	Dec-2024
33	68462-180-22	19230170	Dec-2024
34	68462-180-22	19230572	Jan-2025
35	68462-180-22	19230607	Jan-2025
36	68462-180-22	19230614	Jan-2025
37	68462-180-22	19230628	Jan-2025
38	68462-180-22	19230631	Jan-2025
39	68462-180-22	19230874	Feb-2025
40	68462-180-22	19230925	Feb-2025
41	68462-180-22	19230941	Feb-2025
42	68462-180-22	19230957	Feb-2025
43	68462-180-22	19230976	Feb-2025
44	68462-180-22	19231232	Feb-2025
45	68462-180-22	19231238	Feb-2025
46	68462-180-22	19231282	Feb-2025
47	68462-180-22	19231285	Feb-2025

Recall of these batches have been initiated due to an out-of-specification result reported for the Assay test for batch# 19223615 at the 18 months long-term (25°C/60% RH) stability time point. The age of the batch at the time of testing was 23 months from the date of batch manufacturing and the shelf-life of the batch is 24 months with an expiry of August 2024.

Glenmark Pharmaceuticals Inc. USA 750 Corporate Drive, Mahwah, NJ 07430
T: 1 201 684 8000 F: 1 201 831 0080 www.glenmarkpharma.com/usa

As an impact assessment, reserve samples of seven (7) batches aging from 21 to 24 months old were tested for the test of assay. Out of these seven (7) batches, three (3) batches do not comply with the specification. The remaining four (4) batches do comply with the specification; however, towards the lower side of the limit.

Please see the details of product batches listed in the above table and refer to the enclosed product labels for ease in identifying the product.

Please examine your inventory and if you have any inventory available that pertains to the batches as specified in above table then quarantine these batches immediately. Glenmark Pharmaceuticals, Inc. initiated shipment of this product on October 25th, 2022.

Glenmark is requesting the batches specified in the above table to be returned to Inmar Rx Solutions (address below) using the Postage Paid Product Return label that was provided in your Recall Return Packet.

Inmar Rx Solutions
3845 Grand Lakes Way
Grand Prairie, TX 75050

Please complete and return the enclosed response form preferably within 72 hours of receipt of this notification. Please either fax your response to 817-868-5362 or email to Rxrecalls@Inmar.com.

If you have any questions regarding your recall return please contact Inmar at 877-899-0981

Inmar office hours are Monday through Friday, from 9am to 5pm EST.

This recall is being made with the knowledge of the Food and Drug Administration.

Glenmark Pharmaceuticals Inc. USA 750 Corporate Drive, Mahwah, NJ 07430
T: 1 201 684 8000 F: 1 201 831 0080 www.glenmarkpharma.com/usa

Thank you for your cooperation,

Sincerely,

GLENMARK PHARMACEUTICALS INC., USA

Thomas Callaghan

Digitally signed by Thomas Callaghan
Date: 2024.08.30 07:57:48 -04'00'

Thomas Callaghan

Executive Director - Regulatory Affairs, North America

US Agent for Glenmark Pharmaceuticals

Enclosure(s):

Product Labels

Recall Return Response Form

Glenmark Pharmaceuticals Inc. USA 750 Corporate Drive, Mahwah, NJ 07430
T: 1 201 684 8000 F: 1 201 831 0080 www.glenmarkpharma.com/usa

Reduction in Tube Length

SAME SIZE ARTWORK
CARTON SIZE: 125 mm X 34 mm X 27 mm



Prathyusha Reddy Challa
Digitally signed by Prathyusha Reddy Challa
Date: 2019.02.25 14:13:25 -05'00'

GLENMARK PHARMACEUTICALS LTD.			
PRODUCT NAME: Mupirocin Ointment	DATE:	PANTONE SHADE NO: BLACK 186 C 364 C	
ITEM CODE: PE51740 VERSION: 0219-1	PKG. DEV.:	Item code, Version, Consistency of Design, overprint area, Pack size, Dimensions & Layout	
PHARMACODE: 874	RA	Regulatory Text	
COUNTRY: USA	QA:	Entire Text	
LOCATION: COLVALE - GOA	PRODUCTION:	Machine Suitability	
PACK : CARTON - 22 g	REMARKS:		
ACTUAL SIZE: 125 mm x 34 mm x 27 mm			
SPECIFICATION: 300 GSM ITC Cyber XL with Aqua varnish except for the area marked			

Dr. Qun Luo
Digitally signed by Dr. Qun Luo
Date: 2019.02.25 14:36:58 -05'00'

Carole Capella
Digitally signed by Carole Capella
Date: 2019.02.25 14:48:07 -05'00'

Printed Perforation

PATIENT INFORMATION
Mupirocin (mue-PIR-oh-sin)
Ointment

What is mupirocin ointment?
Mupirocin ointment is a prescription medicine used on the skin (topical use) to treat a skin infection called impetigo that is caused by bacteria called *Staphylococcus aureus* and *Streptococcus pyogenes*. It is not known if mupirocin ointment is safe and effective in children under 2 months of age.

Who should not use mupirocin ointment?
Do not use mupirocin ointment if:
- you are allergic to mupirocin or any of the ingredients in mupirocin ointment. See the end of this Patient Information leaflet for a complete list of the ingredients in mupirocin ointment.

What should I tell my healthcare provider before using mupirocin ointment?
Before using mupirocin ointment, tell your healthcare provider about all of your medical conditions including if you:
- have kidney problems
- are pregnant or plan to become pregnant. It is not known if mupirocin ointment will harm your unborn baby.
- are breastfeeding or plan to breastfeed. It is not known if mupirocin ointment passes into your breast milk. You and your healthcare provider should decide if you can use mupirocin ointment while breastfeeding.

Tell your healthcare provider about all of the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Do not mix mupirocin ointment with other lotions, creams, or ointments.

How should I use mupirocin ointment?
- **Mupirocin ointment is for use on the skin (topical).** Do not get mupirocin ointment in your eyes, nose, mouth, or vagina (mucosal surfaces).
- Use mupirocin ointment exactly as your healthcare provider tells you to use it.
- Apply a small amount of mupirocin ointment, with a cotton swab or gauze pad, to the affected area 3 times each day.
- It is important that you take the full course of mupirocin ointment. Do not stop early because your symptoms may disappear before the infection is fully cleared.
- Wash your hands **before and after** applying mupirocin ointment.
- After applying mupirocin ointment, you may cover the treated area with a clean gauze pad, unless your healthcare provider has told you to leave it uncovered.
- Talk to your healthcare provider if your skin does not improve after 3 to 5 days of treatment with mupirocin ointment.
- If you are breastfeeding and use mupirocin ointment on your breast or nipple, wash the area well before breastfeeding your child.

What are the possible side effects of mupirocin ointment?
Mupirocin ointment may cause serious side effects, including:
- **severe allergic reactions.** Stop using mupirocin ointment and call your healthcare provider or go to the nearest emergency room right away if you have any of the following signs or symptoms of a severe allergic reaction:
  - hives
  - trouble breathing or wheezing
  - swelling of your face, lips, mouth, or tongue
  - dizziness, fast heartbeat or pounding in your chest
  - a rash over your whole body
- **eye irritation.** Do not get mupirocin ointment in your eyes. If mupirocin ointment gets in your eyes, rinse your eyes well with water.
- **irritation in the area mupirocin ointment is used.** Stop using mupirocin ointment and call your healthcare provider if you develop an irritation, severe itching, or a rash while using mupirocin ointment.

PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT

21 mm 21 mm

150 mm

GLENMARK PHARMACEUTICALS LTD

PRODUCT NAME:	MUPIROCIN OINTMENT 2% US LF
ITEM CODE:	PE56801 — VERSION: 0821-1
PHARMACODE:	NA — BARCODE: 56801
COUNTRY:	USA
LOCATION:	GOA
PACK:	21 x 150 mm
ACTUAL SIZE:	240 x 430 mm
SPECIFICATION:	28 GSM Bible Paper

DATE: 24-08-2021	PANTONE SHADE NO: BLACK	
PKG. DEV.:	Item code Version, Consistency of Design, overprint area, Pack size, Dimensions & Layout	Pradnya Kadam
RA	Regulatory Text	
PRODUCTION:	Machine Suitability	
QA:	Entire Text	Vikram Desai
REMARKS:		

FCPDC001/01.00

Webtech Industries — Font: Helvetica Condensed. Size 6 pt. & 10 pt.

May Breedlove — Digitally signed by May Breedlove Date: 2021.09.08 08:49:46 -04'00'

Carole Capella — Digitally signed by Carole Capella Date: 2021.09.08 10:01:35 -04'00'

Kristin DiStefano — Digitally signed by Kristin DiStefano Date: 2021.09.08 10:14:32 -04'00'



Figure 1. Structure of Mupirocin, USP

Each gram of Mupirocin Ointment USP, 2% contains 20 mg mupirocin, USP in a water-miscible ointment base (polyethylene glycol ointment, N.F.) consisting of polyethylene glycol 400 and polyethylene glycol 3350.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Mupirocin is an RNA synthetase inhibitor antibacterial *[see Microbiology (12.4)]*.

12.3 Pharmacokinetics

Absorption.
Application of ¹⁴C-labeled mupirocin ointment to the lower arm of normal male subjects followed by occlusion for 24 hours showed no measurable systemic absorption (less than 1.1 nanogram mupirocin per milliliter of whole blood). Measurable radioactivity was present in the stratum corneum of these subjects 72 hours after application.

The effect of the concurrent application of mupirocin ointment with other topical products has not been studied *[see Dosage and Administration (2)]*.

Elimination.
In a trial conducted in 7 healthy adult male subjects, the elimination half-life after intravenous administration of mupirocin was 20 to 40 minutes for mupirocin and 30 to 80 minutes for monic acid.

Metabolism: Following intravenous or oral administration, mupirocin is rapidly metabolized. The principal metabolite, monic acid, demonstrates no antibacterial activity.

Excretion: Monic acid is predominantly eliminated by renal excretion.

12.4 Microbiology

Mupirocin is an RNA synthetase inhibitor antibacterial produced by fermentation using the organism *Pseudomonas fluorescens*.

Mechanism of Action.
Mupirocin inhibits bacterial protein synthesis by reversibly and specifically binding to bacterial isoleucyl-transfer RNA (tRNA) synthetase.

Mupirocin is bactericidal at concentrations achieved by topical administration. Mupirocin is highly protein bound (greater than 97%) and the effect of wound secretions on the minimum inhibitory concentrations (MICs) of mupirocin has not been determined.

Resistance.
When mupirocin resistance occurs, it results from the production of a modified isoleucyl-tRNA synthetase, or the acquisition of, by genetic transfer, a plasmid mediating a new isoleucyl-tRNA synthetase. High-level plasmid-mediated resistance (MIC ≥512 mcg/mL) has been reported in increasing numbers of isolates of *S. aureus* and with higher frequency in coagulase-negative staphylococci. Mupirocin resistance occurs with greater frequency in methicillin-resistant than methicillin-susceptible staphylococci.

Cross-Resistance.
Due to its mode of action, mupirocin does not demonstrate cross-resistance with other classes of antimicrobial agents.

Antimicrobial Activity.
Mupirocin has been shown to be active against susceptible isolates of *S. aureus* and *S. pyogenes*, both *in vitro* and in clinical trials *[see Indications and Usage (1)]*. The following *in vitro* data are available, but their clinical significance is unknown. Mupirocin is active against most isolates of *Staphylococcus epidermidis*.

Susceptibility Test Methods.
High-level mupirocin resistance (≥512 mcg/mL) may be determined using standard disk diffusion or broth microdilution tests.[1,2] Because of the occurrence of mupirocin resistance in methicillin-resistant *S. aureus* (MRSA), it is appropriate to test MRSA populations for mupirocin susceptibility prior to the use of mupirocin using a standardized method.[3,4,5]

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

Long-term studies in animals to evaluate carcinogenic potential of mupirocin have not been conducted.

Results of the following studies performed with mupirocin calcium or mupirocin sodium *in vitro* and *in vivo* did not indicate a potential for genotoxicity: rat primary hepatocyte unscheduled DNA synthesis, sediment analysis for DNA strand breaks, *Salmonella* reversion test (Ames), *Escherichia coli* mutation assay, metaphase analysis of human lymphocytes, mouse lymphoma assay, and bone marrow micronuclei assay in mice.

In a fertility/reproductive performance study (with dosing through lactation), mupirocin administered subcutaneously to male and female rats at doses up to 100 mg per kg per day which is 14 times the human topical dose (approximately 60 mg mupirocin per day) based on calculations of dose divided by the entire body surface area, did not result in impaired fertility or impaired reproductive performance attributable to mupirocin.

14 CLINICAL STUDIES

The efficacy of topical mupirocin ointment in impetigo was tested in 2 trials. In the first, subjects with impetigo were randomized to receive either mupirocin ointment or vehicle placebo 3 times daily for 8 to 12 days. Clinical efficacy rates at end of therapy in the evaluable populations (adults and pediatric subjects included) were 71% for mupirocin ointment (n = 49) and 35% for vehicle placebo (n = 51). Pathogen eradication rates in the evaluable populations were 94% for mupirocin ointment and 62% for vehicle placebo.

In the second trial, subjects with impetigo were randomized to receive either mupirocin ointment 3 times daily or 30 to 40 mg per kg oral erythromycin ethylsuccinate per day (this was an unblinded trial) for 8 days. There was a follow-up visit 1 week after treatment ended. Clinical efficacy rates at the follow-up visit in the evaluable populations (adults and pediatric subjects included) were 93% for mupirocin ointment (n = 29) and 78.5% for erythromycin (n = 28). Pathogen eradication rates in the evaluable populations were 100% for both test groups.

Pediatrics
There were 91 pediatric subjects aged 2 months to 15 years in the first trial described above. Clinical efficacy rates at end of therapy in the evaluable populations were 78% for mupirocin ointment (n = 42) and 36% for vehicle placebo (n = 48). In the second trial described above, all subjects were pediatric except 2 adults in the group receiving mupirocin ointment. The age range of the pediatric subjects was 7 months to 13 years. The clinical efficacy rate for mupirocin ointment (n = 27) was 89%, and for erythromycin it was unchanged (78.5%).

15 REFERENCES

1. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Susceptibility Testing. Twenty-sixth Informational Supplement.* CLSI document M100-S26. Clinical and Laboratory Standards Institute, 950 West Valley Rd., Suite 2500, Wayne, PA 19087, USA, 2016.
2. Patel J, Gorwitz RJ, et al. Mupirocin Resistance. *Clinical Infectious Diseases.* 2009; 49(6): 935-41
3. Clinical and Laboratory Standards Institute (CLSI). *Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard – Tenth Edition.* CLSI document M07-A10. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
4. Clinical and Laboratory Standards Institute (CLSI). *Performance Standards for Antimicrobial Disk Diffusion Susceptibility Tests, Approved Standard – Twelfth Edition.* CLSI document M02-A12. Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015
5. Finlay JE, Miller LA, Poupard JA. Interpretive criteria for testing susceptibility of staphylococci to mupirocin. *Antimicrob Agents Chemother.* 1997; 41(5):1137-1139.

16 HOW SUPPLIED/STORAGE AND HANDLING

Each gram of Mupirocin Ointment USP contains 20 mg mupirocin, USP in a water-miscible ointment base.

Mupirocin Ointment USP, 2% is supplied in 22-gram tubes.

NDC 68462-180-22   22-gram tube (1 tube per carton)

Store at 20°C to 25°C (68°F to 77°F) [see USP Controlled Room Temperature].

17 PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Patient Information).

Advise the patient to administer mupirocin ointment as follows:

- Use mupirocin ointment only as directed by the healthcare provider. It is for external use only. Avoid contact of mupirocin ointment with the eyes. If mupirocin ointment gets in the eyes, rinse thoroughly with water.
- Do not use mupirocin ointment in the nose.
- Wash your hands before and after applying mupirocin ointment.
- Use a gauze pad or cotton swab to apply a small amount of mupirocin ointment to the affected area. The treated area may be covered by gauze dressing if desired.
- Report to the healthcare provider any signs of local adverse reactions. Mupirocin ointment should be stopped and the healthcare provider contacted if irritation, severe itching, or rash occurs.
- Report to the healthcare provider or go to the nearest emergency room if severe allergic reactions, such as swelling of the lips, face, or tongue, or wheezing occur *[see Warnings and Precautions (5.1)]*.
- If impetigo has not improved in 3 to 5 days, contact the healthcare provider.

Trademarks are the property of their respective owners.

Manufactured by:
Glenmark Pharmaceuticals Limited
Colvale-Bardez, Goa 403513, India

Manufactured for:

glenmark
Glenmark Pharmaceuticals Inc., USA
Mahwah, NJ 07430

Questions? 1 (888) 721-7115
www.glenmarkpharma-us.com

August 2021

PE56801 0821-1

PHARMACIST-DETACH HERE AND GIVE INSTRUCTIONS TO PATIENT

- **a type of diarrhea called *clostridium difficile*-associated diarrhea (CDAD).** CDAD may happen in people who use or have used medicine to treat bacterial infections. The severity of CDAD can range from mild diarrhea to severe diarrhea that may cause death (fatal colitis). Call your healthcare provider or go to the nearest emergency room right away if you have diarrhea while using or after you stop using mupirocin ointment.
- **risk of absorption of polyethylene glycol through the skin.** Mupirocin ointment contains polyethylene glycol, which in large amounts can cause kidney damage. You should not apply mupirocin ointment to open skin wounds or damaged skin, especially if you have kidney problems.
- **Increased risk of infection at IV (intravenous) sites.** Mupirocin ointment should not be used on skin that is near an IV (intravenous) site.

The most common side effects of mupirocin ointment include:

- burning
- stinging or pain
- itching

These are not all the possible side effects of mupirocin ointment. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

How should I store mupirocin ointment?

- Store mupirocin ointment at room temperature between 68°F to 77°F (20°C to 25°C).
- **Keep mupirocin ointment and all medicines out of the reach of children.**

General information about the safe and effective use of mupirocin ointment
Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use mupirocin ointment for a condition for which it was not prescribed. Do not give mupirocin ointment to other people, even if they have the same symptoms that you have. It may harm them. You can ask your pharmacist or healthcare provider for information about mupirocin ointment that is written for health professionals.

What are the ingredients in mupirocin ointment?
Active ingredient: mupirocin
Inactive ingredients: polyethylene glycol 400 and polyethylene glycol 3350

Trademarks are the property of their respective owners.

Manufactured by:
Glenmark Pharmaceuticals Limited
Colvale-Bardez, Goa 403513, India

Manufactured for:

glenmark
Glenmark Pharmaceuticals Inc., USA
Mahwah, NJ 07430

Questions? 1 (888) 721-7115
www.glenmarkpharma-us.com

This Patient Information has been approved by the U.S. Food and Drug Administration. Revised: August 2021

Printed Perforation

GLENMARK PHARMACEUTICALS LTD	DATE: 24-08-2021	PANTONE SHADE NO: BLACK		
PRODUCT NAME: MUPIROCIN OINTMENT 2% US LF	PKG. DEV.:	Item code, Version, Consistency of Design, overprint area, Pack size, Dimensions & Layout	Pradnya Kadam	Digitally signed by Pradnya Kadam
ITEM CODE: PE56801 VERSION: 0821-1				
PHARMACODE: NA BARCODE: 56801	RA	Regulatory Text		
COUNTRY: USA	PRODUCTION:	Machine Suitability		
LOCATION: GOA	QA:	Entire Text	Vikram Desai (900336461) Sr. Officer QA	
PACK: 21 x 150 mm	REMARKS:			
ACTUAL SIZE: 240 x 430 mm				
SPECIFICATION: 28 GSM Bible Paper				
				FCPDC001/01.00

Webtech Industries   Font: Helvetica Condensed. Size: 6 pt. & 10 pt.

May Breedlove — Digitally signed by May Breedlove Date: 2021.09.08 08:49:57 -04'00'

Carole Capella — Digitally signed by Carole Capella Date: 2021.09.08 10:01:45 -04'00'

Kristin DiStefano — Digitally signed by Kristin DiStefano Date: 2021.09.08 10:14:47 -04'00'

Glenmark
A new way for a new world

Glenmark Pharmaceuticals Inc.
RECALL RETURN RESPONSE FORM
MUPIROCIN OINTMENT USP, 2% 22 g Tube pack
NDC 68462-180-22
Wholesale Level
08/30/2024

Please fill out this form completely. By doing so, this will acknowledge that you have read and understood the recall instructions and have taken the appropriate action.

Customer Name:	DEA#:	
DEA # is required, if it is not provided, the processing of your form will be delayed.		
Address:		
City:	State:	Zip:
Contact Name (Please Print):		
Telephone#:	Email:	
Contact Signature:	Date:	
DEBIT MEMO# (If unsure, leave blank):		

Wholesaler Information if not directly purchased from Glenmark Pharmaceuticals Inc.:

Wholesaler Name:	DEA#:	
City:	State:	Zip:

I have checked my stock and communicated to my customers at the appropriate level:

□ I confirm that all locations that received the impacted products have been notified to the Wholesale level _____(Initial and date)

□ I do not have any stock of the recalled items. **OR**

□ I have quarantined and listed in the box below the quantity of recalled units and I will be returning to Inmar, as soon as possible. Upon receipt of this Response Form, Inmar, will issue return authorization label(s) Please indicate the # of needed box labels_____.

Sr. No.	Item Description	NDC#	Lot#	Exp. Date	Total Full/Sealed and Partial/Open Tube Count
1	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223615	Aug-2024	
2	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223537	Aug-2024	
3	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223544	Aug-2024	
4	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223568	Aug-2024	

Sr. No.	Item Description	NDC#	Lot#	Exp. Date	Total Full/Sealed and Partial/Open Tube Count
5	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223593	Aug-2024	
6	MUPIROCIN OINTMENT USP 2%	68462-180-22	19223641	Aug-2024	
7	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224055	Sep-2024	
8	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224281	Sep-2024	
9	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224307	Sep-2024	
10	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224321	Sep-2024	
11	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224341	Sep-2024	
12	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224467	Sep-2024	
13	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224525	Oct-2024	
14	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224542	Oct-2024	
15	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224560	Oct-2024	
16	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224580	Oct-2024	
17	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224990	Nov-2024	
18	MUPIROCIN OINTMENT USP 2%	68462-180-22	19224998	Nov-2024	
19	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225014	Nov-2024	
20	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225033	Nov-2024	
21	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225293	Nov-2024	
22	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225304	Nov-2024	
23	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225320	Nov-2024	
24	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225349	Nov-2024	
25	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225367	Nov-2024	
26	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225379	Nov-2024	
27	MUPIROCIN OINTMENT USP 2%	68462-180-22	19225401	Nov-2024	
28	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230115	Dec-2024	
29	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230123	Dec-2024	
30	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230132	Dec-2024	
31	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230137	Dec-2024	
32	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230167	Dec-2024	
33	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230170	Dec-2024	
34	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230572	Jan-2025	
35	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230607	Jan-2025	
36	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230614	Jan-2025	
37	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230628	Jan-2025	
38	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230631	Jan-2025	
39	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230874	Feb-2025	
40	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230925	Feb-2025	
41	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230941	Feb-2025	
42	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230957	Feb-2025	
43	MUPIROCIN OINTMENT USP 2%	68462-180-22	19230976	Feb-2025	

Sr. No.	Item Description	NDC#	Lot#	Exp. Date	Total Full/Sealed and Partial/Open Tube Count
44	MUPIROCIN OINTMENT USP 2%	68462-180-22	19231232	Feb-2025	
45	MUPIROCIN OINTMENT USP 2%	68462-180-22	19231238	Feb-2025	
46	MUPIROCIN OINTMENT USP 2%	68462-180-22	19231282	Feb-2025	
47	MUPIROCIN OINTMENT USP 2%	68462-180-22	19231285	Feb-2025	

If you have any questions regarding this form or product return please contact Inmar at 877-899-0981

Office hours 9am to 5pm EST Mon thru Fri.

Please fax this form to: 1-817-868-5362 or E-mail rxrecalls@inmar.com
Recall Event ID RCL221-24 / N131208